Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 15, Number 8—August 2009

Research

Increase in Pneumococcus Macrolide Resistance, United States

Stephen G. JenkinsComments to Author  and David J. Farrell
Author affiliations: Weill Cornell Medical College, New York, NY, USA (S.G. Jenkins); Quotient Bioresearch Ltd, London, UK (D.J. Farrell)

Main Article

Table 2

Macrolide resistance genotypes, year 5 (2004-2005) and year 6 (2005–2006) of the PROTEKT US surveillance study*

   Genotype    No. isolates (% of ERSP)†
   Year 5 (n = 1,907)    Year 6 (n = 2,381)
   erm(B)    310 (16.3)    448 (18.8)
   mef(A)    1,172 (61.5)    1,282 (53.8)
   erm(B) + mef(A)    377 (19.8)    575 (24.1)
   erm(TR)    2 (0.1)    0
   Ribosomal mutations    26 (1.4)    41 (1.7)

   *PROTEKT US, Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin, United States; ERSP, erythromycin-resistant Streptococcus pneumoniae.
   †A total of 20 isolates in year 5 and 35 isolates in year 6 were not viable for genotyping.

Main Article

TOP